UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM SD
Specialized Disclosure Report
Pacific Biosciences of California, Inc.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware |
| 001-34899 |
| 16-1590339 |
(State or other jurisdiction of incorporation) |
| (Commission File Number) |
| (IRS Employer Identification No.) |
1305 O’Brien Drive
Menlo Park, California 94025
(Address of principal executive offices, including zip code)
Brett Atkins
General Counsel and Corporate Secretary
(650) 521-8000
(Name and telephone number, including area code, of the person to contact in connection with this report)
Check the appropriate box to indicate the rule pursuant to which this form is being filed, and provide the period to which the information in this form applies:
☒Rule 13p-1 under the Securities Exchange Act (17 CFR 240.13p-1) for the reporting period from January 1 to December 31, 2021.
☐Rule 13q-1 under the Securities Exchange Act (17 CFR 240.13q-1) for the fiscal year ended __________.
Section 1.Conflict minerals disclsosure
Item 1.01 Conflict Minerals Disclosure and Report
A copy of Pacific Biosciences of California, Inc.’s (the “Company’s”) Conflict Minerals Report for the reporting period January 1, 2021 to December 31, 2021 is provided as Exhibit 1.01 hereto and is publicly available at www.pacb.com.
Item 1.02 Exhibit
In accordance with Rule 13p-1, and this Form SD, the Company is hereby filing its Conflict Minerals Report for the calendar year ended December 31, 2021 as Exhibit 1.01 to this report.
Section 2.Resource Extraction Issuer Disclosure
Item 2.01 Resource Extraction Issuer Disclosure and Report
Not applicable.
Section 3.Exhibits
The following exhibits are filed as part of this report:
Item 3.01 Exhibits
Exhibit 1.01 — 2021 Conflict Minerals Report of Pacific Biosciences of California, Inc. as required by Items 1.01 and 1.02 of this Form SD.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Susan |
|
|
|
|
|
Pacific Biosciences of California, Inc. | ||
|
| |
By: |
| /s/ Susan G. Kim |
|
| Susan G. Kim Chief Financial Officer |
Date: May 25, 2022
EXHIBIT INDEX
5 |
|
Exhibit No. | Description |
1.01 |
